Literature DB >> 20413044

Thiazolidinedione drugs and cardiovascular risks: a science advisory from the American Heart Association and American College Of Cardiology Foundation.

Sanjay Kaul, Ann F Bolger, David Herrington, Robert P Giugliano, Robert H Eckel.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20413044     DOI: 10.1016/j.jacc.2010.02.014

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


× No keyword cloud information.
  19 in total

Review 1.  Incretin-related drug therapy in heart failure.

Authors:  Amanda R Vest
Journal:  Curr Heart Fail Rep       Date:  2015-02

2.  Management of type-2 diabetes mellitus in adults: focus on individualizing non-insulin therapies.

Authors:  Luigi Brunetti; Julie Kalabalik
Journal:  P T       Date:  2012-12

3.  Rosiglitazone inhibits vascular KATP channels and coronary vasodilation produced by isoprenaline.

Authors:  Lei Yu; Xin Jin; Yang Yang; Ningren Cui; Chun Jiang
Journal:  Br J Pharmacol       Date:  2011-12       Impact factor: 8.739

4.  Rosiglitazone selectively inhibits K(ATP) channels by acting on the K(IR) 6 subunit.

Authors:  Lei Yu; Xin Jin; Ningren Cui; Yang Wu; Zhenda Shi; Daling Zhu; Chun Jiang
Journal:  Br J Pharmacol       Date:  2012-09       Impact factor: 8.739

Review 5.  Glycemic variability and glycemic control in the acutely ill cardiac patient.

Authors:  Jared Moore; Kathleen Dungan
Journal:  Heart Fail Clin       Date:  2012-08-09       Impact factor: 3.179

Review 6.  Treating Disease Mechanisms in Patients With Heart Failure and Diabetes Mellitus.

Authors:  Amanda Trang; David Aguilar
Journal:  Curr Heart Fail Rep       Date:  2017-12

Review 7.  Congestive heart failure and diabetes mellitus: balancing glycemic control with heart failure improvement.

Authors:  Saifullah Nasir; David Aguilar
Journal:  Am J Cardiol       Date:  2012-11-06       Impact factor: 2.778

8.  Pharmacogenetics of Anti-Diabetes Drugs.

Authors:  Johanna K Distefano; Richard M Watanabe
Journal:  Pharmaceuticals (Basel)       Date:  2010-08-01

9.  Differential sensitivities of the vascular K(ATP) channel to various PPAR activators.

Authors:  Yingji Wang; Lei Yu; Ningren Cui; Xin Jin; Daling Zhu; Chun Jiang
Journal:  Biochem Pharmacol       Date:  2013-03-13       Impact factor: 5.858

10.  Can the electrophysiological action of rosiglitazone explain its cardiac side effects?

Authors:  A Szebeni; N Szentandrássy; P Pacher; J Simkó; P P Nánási; V Kecskeméti
Journal:  Curr Med Chem       Date:  2011       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.